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Abstract
Patients with schizophrenia often present mild to severe cognitive deficits which contribute to their
social disability. Second-generation antipsychotics have shown only mild to moderate beneficial
effects on cognition. The present case report suggests cognitive enhancing effects of aripiprazole,
a dopamine partial agonist, shown to increase dopamine release in prefrontal cortex in animal
studies.
The patient was in his first-episode of schizophrenia, and had no previous exposure to first-
generation antipsychotics. Before schizophrenia onset his cognitive functioning was poor and he
could not attend regular courses to reach his high school degree; he started but was not able to
attend the University courses for several years.
After schizophrenia onset, he was treated, in sequence, with olanzapine, amisulpride and
aripiprazole. During treatment with the first two second-generation antipsychotics, positive
symptoms markedly improved while cognitive functioning remained poor. During treatment with
aripiprazole, clinical remission was obtained and the patient was able to attend university courses
and pass several examinations. Social functioning was markedly improved.
Aripiprazole demonstrated cognitive enhancing effects in this patient. These effects were long-
lasting and paralleled by a positive impact on social functioning.
Background
Patients with schizophrenia often present mild to severe
cognitive deficits which contribute to their social disabil-
ity [1,2]. These deficits are present during the first episode
of the illness and often persist after remission of acute psy-
chotic symptoms. First-generation antipsychotics (FGAs)
do not alleviate cognitive dysfunctions and might have a
detrimental effect on cognition through the induction of
extrapyramidal side effects (EPS). Second-generation
antipsychotics (SGAs) have shown beneficial effects on
cognition, but it is not clear whether these effects reflect a
direct action of the drugs or are secondary to the reduction
of EPS [3,5]. Aripiprazole, a dopamine partial agonist, is
among the drugs under investigation as potential cogni-
tive-enhancers. Its potential favorable impact on cogni-
tion might be related to an increased release of dopamine
in prefrontal cortex and hippocampus, demonstrated in
animal studies [6]. An open label study [7] seems to sug-
gest a beneficial effect of aripiprazole on some aspects of
cognitive functioning in patients with schizophrenia, in
comparison with olanzapine. However, a true cognitive-
enhancing effect has never been demonstrated in humans.
We describe hereafter the case of a patient in his first-epi-
sode of schizophrenia, in which cognitive-enhancing
effects of aripiprazole were observed.
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When the patient was first seen at the Center for Psychotic
Disorders of our University Department of Psychiatry, he
was a 27 year-old man in his first episode of schizophre-
nia (undifferentiated subtype). The onset of schizophre-
nia was estimated at 26 years of age. He had experienced
school difficulties and could not attend regular courses to
reach his high school degree. He started but was not able
to attend the University courses for several years before
schizophrenia onset.
He had been never treated with FGAs and was experienc-
ing an acute psychotic relapse two months after the inter-
ruption of treatment with olanzapine (10 mg/die).
According to his parents and the referring doctor, he had
responded well to olanzapine, therefore, the drug was
reintroduced (10 mg/die) while starting cognitive psycho-
therapy to increase motivation to treatment. Acute psy-
chotic symptoms and active withdrawal improved in 1
month; however, he presented difficulty in concentrating
and attention deficits. In the following 5 months, positive
symptoms markedly improved (46% reduction of the pre-
drug Positive and Negative Symptoms Scale (PANSS) pos-
itive factor score), but the patient experienced excessive
weight increase (about 10 Kg with respect to pre-drug
period) and poor response of cognitive dysfunctions
(23% reduction of PANSS scores on the cognitive factor),
as well as of social disability (Social and Occupational
Functioning Assessment Scale (SOFAS) = 51). He could
not persist in either work or study activities for more than
a few days. He dropped from drug treatment after 10
months. He experienced an acute psychotic relapse and
gave his consent to restart an antipsychotic drug after 2
months. Due to the limited effect of olanzapine on cogni-
tive dysfunctions, the patient was started on amisulpride
(gradually titrated to 600 mg/die). Psychotic symptoms
markedly improved in 6 weeks, while cognitive dysfunc-
tions presented a modest amelioration: he continued to
spend most of the morning hours in bed, experienced
learning deficits and could not study. After 6 months on
amisulpride, he showed a marked improvement on
PANSS positive factor (with 48% reduction of the pre-
drug score) and a modest improvement on the cognitive
factors (25% reduction of pre-drug score). His weight did
not return to baseline levels, although no further increase
was observed. After 6 months of treatment, the patient
was shifted to aripiprazole (10 mg/die). In 3 months of
treatment with the latter drug he attained full clinical
remission. PANSS positive, negative and cognitive factors
showed marked improvement (pre-drug score reduction
of 61%, 43% and 64%, respectively). On SOFAS the
patient reached the score of 70. During the first 10 months
of treatment, he returned to his baseline weight. He was
able to attend several university courses, to study and
learn with regularity, and in 1 year of treatment he could
pass 6 exams. He was feeling "..normal" and willing "...to
manage life without drugs". He decided to stop medica-
tion without doctor's consent. In the following two
months, he experienced a relapse and gave his consent to
restart aripiprazole. The drug was reintroduced at 10 mg/
die, but it was deemed appropriate to increase the dosage
at 15 mg/die after 3 weeks. Clinical remission and a
marked improvement of cognitive dysfunctions were
attained in 4 months. He was able to attend 3 courses reg-
ularly and to pass one exam during the first 5 months of
treatment. He could make new friendships among univer-
sity students and started to attend a political group. After
6 months of treatment with aripiprazole, PANSS positive,
negative and cognitive factors attained the largest
improvement (reduction of pre-drug scores of 60%, 59%
and 57%, respectively) and the SOFAS score increased to
80. He gained about 3 Kg during the first 2 months and
then stabilized his weight.
Discussion
In our opinion this case report suggests remarkable effects
of aripiprazole on ecological, real-life indicators of cogni-
tive functions, i.e., the ability to attend University courses
and to pass formal examinations, in a patient who, before
schizophrenia onset, presented poor cognitive function-
ing and could not attend regular courses to reach his high
school degree. Aripiprazole also determined a marked
improvement of psychosocial functioning, as assessed by
SOFAS score of 80. These results were observed with arip-
iprazole but not with either olanzapine or amisulpride, in
spite of the positive effects of these two antipsychotic
drugs on both positive and negative symptoms.
SGAs have shown beneficial effects on cognition [3,5,7-
9], and hypothesized mechanisms include a lower pro-
pensity, with respect to FGAs, to induce cognitive blunting
due to a low affinity for the dopamine D2 receptor, an
action on the 5-HT(1A) receptor, which promotes a
release of dopamine in prefrontal cortex, as well as
through neuroprotective action [5,10,11]. Aripiprazole
might have a cognitive-enhancing effects through the last
two of the previous mechanisms, as well as through an
increase of dopamine transmission in prefrontal cortex
and hippocampus [6].
Conclusion
Aripiprazole demonstrated cognitive enhancing effects in
this patient. These effects were long-lasting and paralleled
by a positive impact on social functioning.
Consent
The patient was informed about the nature and aims of
the present case report, and a draft containing all informa-
tion about his history and therapy to be included in thePage 2 of 3
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report was provided to him for comments and queries.
After his approval of the draft, a written informed consent
was obtained.
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